Multicenter, Open-label, Safety and Tolerability Study
Public ClinicalTrials.gov record NCT01649557. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients With Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This will be a multicenter, 52 week, open label study to assess the safety and tolerability of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study will be conducted on an outpatient basis. Enrollment into the study will be drawn from eligible subjects who have completed participation in Study 331-07- 203 and who, in the investigator's judgment, would benefit from continued treatment with oral OPC-34712.
Study identification
- NCT ID
- NCT01649557
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 244 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 67 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2009
- Primary completion
- Jul 31, 2011
- Completion
- Aug 31, 2011
- Last update posted
- Oct 28, 2015
2009 – 2011
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Otsuka Investigational Site | Little Rock | Arkansas | 72211 | — |
| Otsuka Investigational Site | Escondido | California | 92025 | — |
| Otsuka Investigational Site | Garden Grove | California | 92845 | — |
| Otsuka Investigational Site | Long Beach | California | 90813 | — |
| Otsuka Investigational Site | Oceanside | California | 92056 | — |
| Otsuka Investigational Site | Pasadena | California | 91106 | — |
| Otsuka Investigational Site | San Diego | California | 92102 | — |
| Otsuka Investigational Site | San Diego | California | 92123 | — |
| Otsuka Investigational Site | Santa Ana | California | 92701 | — |
| Otsuka Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| Otsuka Investigational Site | Bradenton | Florida | 34208 | — |
| Otsuka Investigational Site | Maitland | Florida | 32751 | — |
| Otsuka Investigational Site | St Louis | Missouri | 63118 | — |
| Otsuka Investigational Site | Cedarhurst | New York | 11516 | — |
| Otsuka Investigational Site | Philadelphia | Pennsylvania | 19139 | — |
| Otsuka Investigational Site | Austin | Texas | 78731 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01649557, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01649557 live on ClinicalTrials.gov.